Phase II study: Radiofrequency ablation of irresectable locally advanced pancreatic cancer

Phase 2

Withdrawn

• Conditions: cancer of the pancreas; Pancreatic cancer; 10015674

• Registration Number: NL-OMON36420
• Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 15

Inclusion Criteria

1. Patients with locally advanced pancreatic cancer
2. No evidence of systemic metastasis, CT scan within 1 month prior to inclusion
3. No serious medical or psychological condition precluding radiofrequency ablation
4. Fully informed written consent given
5. Patients willing to attend for three months follow-up

Exclusion Criteria

1. Patients younger than 18 years
2. Pregnancy
3. Patients with distant metastasis

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary outcome parameter of the phase II study is feasibility and safety. The<br /><br>study will have a follow-up period of 3 months.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary study parameters are tumour downstaging, VAS painscore and hospital<br /><br>stay. </p><br>